ANL logo

ANL Adlai Nortye Ltd.

NASDAQ Global Market · Biotechnology · Healthcare

$9.55
-0.48 (-4.79%)

Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company…

Market Cap: $506.91Mwww.adlainortye.com

Price

No data yet.

Social Signal Score

43
5d
—
30d
—
60d
43
3 mentions
—
90d
43
3 mentions
—
news: 3

Analyst Ratings

1 analyst
Buyconsensus
Strong Buy 0Buy 1Hold 0Sell 0Strong Sell 0
Avg price target$37.33+290.9%
Low $31Median $32High $49
Current Consensus

Revenue

$7.34M
$0.00$2.45M$4.89M$7.34M
Mar 2022Jun 2026

Analyst Estimates

FY2025
$-0.29
$-0.42–$-0.24
2 analysts
FY2026
$-0.18
$-0.28–$-0.11
5 analysts
FY2027
$-0.29
$-0.57–$-0.13
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Yang Lu
Sector
Healthcare
Industry
Biotechnology
Employees
109
Beta
1.16
Country
SG
Piotroski score
3 / 9 (Weak)
Altman Z-score
7.36
www.adlainortye.com